Want to see NAGE full AI Analyst Report?
Top Page
Niagen Bioscience
(NASDAQ:NAGE)
Select Model
Select Model
Rating:69Neutral
Price Target:
$3.50
▲(9.03% Upside)
Action:Downgraded
Date:08/10/26
The score is driven by improved financial fundamentals (profitability, strong margins, and a low-debt balance sheet) and supportive earnings-call guidance reaffirming 10–15% growth. These positives are tempered by weak technical trend signals (price below key moving averages and negative MACD) and execution risks highlighted by recent cash flow timing pressure and competitive/regulatory headwinds.
Positive Factors
Stable, high gross margins
Consistently high gross margins in the low-to-mid 60% range provide durable earnings power, supporting reinvestment in R&D, marketing, and product launches. Margin stability cushions profitability through competitive pressure and funds strategic initiatives without immediate reliance on external financing.
Negative Factors
Inconsistent cash conversion
TTM operating cash flow lagging net income and prior-period cash burn indicate working-capital timing and inventory risks. Inconsistent cash conversion weakens the reliability of reported earnings to fund recurring investments, dividends, or buybacks and raises sensitivity to partner/payment timing shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable, high gross margins
Consistently high gross margins in the low-to-mid 60% range provide durable earnings power, supporting reinvestment in R&D, marketing, and product launches. Margin stability cushions profitability through competitive pressure and funds strategic initiatives without immediate reliance on external financing.
Read all positive factors
Niagen Bioscience (NAGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$241.33M
Dividend YieldN/A
Average Volume (3M)702.29K
Price to Earnings (P/E)15.2
Beta (1Y)0.95
Revenue Growth10.99%
EPS Growth-12.12%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.20
Shares Outstanding79,126,000
10 Day Avg. Volume757,578
30 Day Avg. Volume702,286
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.20Price Target Upside217.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.15
Revenue Forecast (FY)$134.14M
Niagen Bioscience Business Overview & Revenue Model
Company Description
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide....
How the Company Makes Money
Niagen Bioscience makes money primarily by selling NAD+-related dietary supplements and by monetizing its proprietary NR ingredient through ingredient supply arrangements. Key revenue streams include: (1) direct-to-consumer sales of finished suppl...
Niagen Bioscience Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.Positive Updates
Revenue and Profitability
Total revenue of $31.5M ($31.1M excluding divested reference standards), representing a 5% year-over-year increase. Net income of $6.3M and diluted EPS of $0.08 vs $0.07 year-ago.
Negative Updates
Moderate Top-Line Pressure from Key Customers
Two customers ordered less this quarter compared to the prior year, contributing to slower overall growth despite e-commerce strength.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Profitability
Total revenue of $31.5M ($31.1M excluding divested reference standards), representing a 5% year-over-year increase. Net income of $6.3M and diluted EPS of $0.08 vs $0.07 year-ago.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 revenue growth guidance of 10–15% year‑over‑year, calling e‑commerce the primary growth engine (Q1 e‑commerce +14% to $19.2M) and new product launches as upside; Q1 results included $31.5M revenue ($31.1M excl. reference standards, +5% YoY excl. divestiture), TRU NIAGEN $22.4M (+4% YoY), NIAGEN ingredient $8.2M (+2%), gross margin 63.5% (up 10 bps), net income $6.3M (EPS $0.08), cash $66.5M, no debt, and working capital ~$82.3M. They stated selling & marketing spend will increase in absolute dollars and as a percentage of sales (Q1 S&M was 30.7% vs 26.6% LY), now expect G&A to rise $3–4M YoY (revised from prior $4–5M), continue a $20M share‑repurchase program (Q1 repurchases $2.4M), anticipate inventory to decline through the year after a $3.6M inventory build and $1.2M net cash used by operations in Q1, and noted partner order timing (e.g., Watsons) may cause quarterly fluctuations but is expected to improve over the year.Niagen Bioscience Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 129.08M | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M |
| Gross Profit | 82.92M | 83.19M | 61.59M | 50.78M | 42.80M | 41.49M |
| EBITDA | 18.48M | 19.64M | 10.34M | -3.23M | -14.66M | -25.45M |
| Net Income | 15.99M | 17.38M | 8.55M | -4.94M | -16.54M | -27.13M |
Balance Sheet | ||||||
| Total Assets | 106.59M | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M |
| Cash, Cash Equivalents and Short-Term Investments | 66.74M | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M |
| Total Debt | 2.33M | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M |
| Total Liabilities | 24.06M | 29.87M | 22.18M | 26.51M | 25.39M | 26.11M |
| Stockholders Equity | 82.53M | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M |
Cash Flow | ||||||
| Free Cash Flow | 5.67M | 13.14M | 11.95M | 6.97M | -15.43M | -24.57M |
| Operating Cash Flow | 5.95M | 13.44M | 12.11M | 7.12M | -15.10M | -24.16M |
| Investing Cash Flow | 5.03M | -292.00K | -143.00K | -143.00K | -334.00K | -409.00K |
| Financing Cash Flow | -4.71M | 6.98M | 5.37M | -90.00K | 7.65M | 36.09M |
Niagen Bioscience Technical Analysis
Negative
3.21
Price Trends
3.34
Negative
3.83
Negative
4.95
Negative
Market Momentum
-0.10
Positive
40.55
Neutral
22.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Negative. The current price of 3.21 is below the 20-day moving average (MA) of 3.22, below the 50-day MA of 3.34, and below the 200-day MA of 4.95, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAGE.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Niagen Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $241.33M | 15.19 | 20.50% | ― | 10.99% | -12.12% | |
64 Neutral | $2.11B | -82.41 | -6.31% | ― | 13520.11% | 74.95% | |
60 Neutral | $2.95B | -9.97 | -40.51% | ― | 34.52% | 41.20% | |
59 Neutral | $1.69B | -18.72 | -15.53% | ― | -2.09% | 91.98% | |
56 Neutral | $897.61M | -3.22 | -207.18% | ― | -7.27% | -48.89% | |
56 Neutral | $1.52B | -4.99 | -29.99% | ― | 1495.93% | 53.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NAGE
Niagen Bioscience
3.02
-7.00
-69.86%
IOVA
Iovance Biotherapeutics
6.98
4.43
173.73%
KURA
Kura Oncology
10.86
3.52
47.96%
VIR
Vir Biotechnology
9.24
4.72
104.42%
FTRE
Fortrea Holdings Inc.
17.41
9.37
116.54%
SEPN
Septerna, Inc.
44.50
32.78
279.69%
Niagen Bioscience Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresProduct-Related Announcements
Niagen Bioscience Reports Strong Q2 Results, Highlights Growth
Positive
Aug 4, 2026
On August 4, 2026, Niagen Bioscience reported second-quarter 2026 results, posting net sales of $29.8 million, including $24.2 million from Tru Niagen, with direct-to-consumer website sales up 23% year-over-year and a gross margin of 64.8%. The co...
Executive/Board ChangesShareholder Meetings
Niagen Bioscience Shareholders Back Board and Governance Measures
Positive
Jun 29, 2026
At Niagen Bioscience’s 2026 Annual Meeting of Stockholders, shareholders elected eight directors, including Frank L. Jaksch Jr., Robert Fried, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, Steven Rubin, and Hamed Shahbazi, to serve until th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.